Similarly, the glucagon-like peptide-1 receptor (GLP-1R) is well established as a therapeutic target for type 2 diabetes and obesity, with GLP-1R agonists effectively lowering glucose levels and promoting weight loss. This evidence concerns the gene GLP1R and obesity disorder.